Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at

Subscribe to WSJ:

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
React to this article
01/29 REGENERON PHARMACEUTICALS : New Findings from Regeneron Pharmaceuticals Inc. Des..
01/28 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Recommended for Approva..
01/27DJAmgen Profit Rises 27% on Higher Sales of Key Drugs -- Update
01/27 Investing in Westchester's biotech surge
01/27 SANOFI : and Regeneron Announce Praluent (alirocumab) Biologics License Applicat..
01/26DJSANOFI : FDA Grants Priority Review for Sanofi and Regeneron's Drug
01/26 REGENERON PHARMACEUTICALS : and Sanofi Announce Praluent™ (alirocumab) Bio..
01/23 REGENERON PHARMACEUTICALS : New Data from Regeneron Pharmaceuticals Inc. Illumin..
01/23 REGENERON PHARMACEUTICALS : Details Findings in Immunoglobulins (Efficacy and sa..
01/23 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Recommended for Appro..
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes